Tomas Jan Heyman
Director/Board Member presso XILIO THERAPEUTICS, INC.
Patrimonio netto: 431 316 $ in data 31/03/2024
Profilo
Tomas Jan Heyman is currently the Chief Executive Officer at Interlaken Therapeutics, Inc. He also holds positions as Chairman at Venatorx Pharmaceuticals, Inc., Director at Exelixis, Inc., Independent Director at OptiNose, Inc., Director at Interuniversitair Micro-Electronica Centrum VZW, Independent Director at Legend Biotech Corp., Independent Director at Xilio Therapeutics, Inc., Independent Director at Akero Therapeutics, Inc., and Independent Director at Invivyd, Inc. In the past, Heyman served as Chairman & Chief Executive Officer at Janssen Pharmaceutica NV, Global Head-Business Development at Johnson & Johnson, and President at Johnson & Johnson Innovation - JJDC, Inc. He also held positions as Director at CVRx, Inc. and International Biomedical Research Alliance, Member-Supervisory Board at Crucell NV, and Vice President-Licensing at Ortho Pharmaceutical Corp.Heyman received a graduate degree from Katholieke Universiteit Leuven and the University of Antwerp.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
EXELIXIS, INC.
0.01% | 31/05/2023 | 18 176 ( 0.01% ) | 431 316 $ | 31/03/2024 |
INVIVYD, INC.
-.--% | 27/03/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
OPTINOSE, INC.
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Posizioni attive di Tomas Jan Heyman
| Società | Posizione | Inizio |
|---|---|---|
| AKERO THERAPEUTICS, INC. | Director/Board Member | 09/06/2020 |
| OPTINOSE, INC. | Director/Board Member | 01/12/2020 |
| INVIVYD, INC. | Director/Board Member | 01/06/2021 |
| LEGEND BIOTECH CORPORATION | Director/Board Member | 02/08/2022 |
| XILIO THERAPEUTICS, INC. | Director/Board Member | 15/09/2022 |
| EXELIXIS, INC. | Director/Board Member | 31/05/2023 |
Venatorx Pharmaceuticals, Inc.
 Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Chairman | 07/03/2023 |
| Interlaken Therapeutics, Inc. | Chief Executive Officer | - |
Interuniversitair Micro-Electronica Centrum VZW
 Interuniversitair Micro-Electronica Centrum VZW Miscellaneous Commercial ServicesCommercial Services Interuniversitair Micro-Electronica Centrum VZW, also known as Imec, is a Belgian business accelerator. The non-profit company is based in Leuven, BE and has subsidiaries in the United States, Taiwan, India, Netherlands, and Belgium. Imec.istart is their main program, which helps startups grow and succeed. The Belgian company was founded in 1984 and has been led by CEO Luc van den Hove since then. | Director/Board Member | 27/04/2012 |
Precedenti posizioni note di Tomas Jan Heyman
| Società | Posizione | Fine |
|---|---|---|
| ░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░ ░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░░░░ ░░░░░░░ ░░░░░░░░░░ ░ ░░░░░ ░░░░ | ░░░░░░░░░ | - |
Formazione di Tomas Jan Heyman
| Katholieke Universiteit Leuven | Graduate Degree |
| University of Antwerp | Graduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 8 |
|---|---|
| JOHNSON & JOHNSON | Health Technology |
| EXELIXIS, INC. | Health Technology |
| OPTINOSE, INC. | Health Technology |
| CVRX, INC. | Health Technology |
| LEGEND BIOTECH CORPORATION | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| AKERO THERAPEUTICS, INC. | Health Technology |
| INVIVYD, INC. | Health Technology |
| Aziende private | 8 |
|---|---|
Crucell NV
 Crucell NV Pharmaceuticals: MajorHealth Technology Crucell NV develops, produces and markets vaccines, proteins and antibodies that prevent and treat infectious diseases. It focuses in the research & development of innovative immunization candidates to fight against tuberculosis, malaria, HIV/AIDS, influenza, rabies, polio and several other diseases which are the global health problems. The firms prod8ucts include Quinvaxem, Epaxal, Hepavax-Gene, Vivotif and Dukoral against paediatric, respiratory and travel or endemic infections. The company was founded by Domenico Valerio on October 9, 2000 and is headquartered in Leiden, Netherlands. | Health Technology |
Venatorx Pharmaceuticals, Inc.
Venatorx Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Venatorx Pharmaceuticals, Inc. develops novel anti-infective agents to address the threat of antibiotic resistance. It offers antibiotic resistant bacteria and Carbapenem-resistant Enterobacteriaceae a family of gram-negative bacteria that are resistant to all known ?-lactam antibiotics, including penicillins, cephalosporins, monobactams, and carbapenems. The company was founded by Christopher J. Burns, Luigi Xerri, and Daniel Pevear in 2010 and is headquartered in Malvern, PA. | Commercial Services |
Johnson & Johnson Innovation - JJDC, Inc.
 Johnson & Johnson Innovation - JJDC, Inc. Investment ManagersFinance Johnson & Johnson Innovation JJDC Inc (Johnson & Johnson Innovation JJDC) is a venture capital subsidiary of Johnson & Johnson founded in 1973. The firm is headquartered in New Brunswick, New Jersey. | Finance |
International Biomedical Research Alliance
 International Biomedical Research Alliance Miscellaneous Commercial ServicesCommercial Services The International Biomedical Research Alliance supports the NIH Oxford-Cambridge Scholars Program and associated global Ph.D. and M.D./Ph.D. training programs based in the Intramural Research Program of the National Institutes of Health. The company was founded in 2005 and is headquartered in Bethesda, MD. | Commercial Services |
Janssen Pharmaceutica NV
 Janssen Pharmaceutica NV Pharmaceuticals: MajorHealth Technology Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium. | Health Technology |
| Ortho Pharmaceutical Corp. | |
Interuniversitair Micro-Electronica Centrum VZW
Interuniversitair Micro-Electronica Centrum VZW Miscellaneous Commercial ServicesCommercial Services Interuniversitair Micro-Electronica Centrum VZW, also known as Imec, is a Belgian business accelerator. The non-profit company is based in Leuven, BE and has subsidiaries in the United States, Taiwan, India, Netherlands, and Belgium. Imec.istart is their main program, which helps startups grow and succeed. The Belgian company was founded in 1984 and has been led by CEO Luc van den Hove since then. | Commercial Services |
| Interlaken Therapeutics, Inc. |
- Borsa valori
- Insiders
- Tomas Jan Heyman
